{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:29:46Z","timestamp":1784575786771,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Advanced prostate cancer (PCa) is still an incurable disease. Still, the field of PSMA-targeted radioligand therapy is developing rapidly and is playing an increasingly important role in the treatment of advanced Pca in the future. As an \u03b1 -particle emitter, Ac-225 shows a potent killing ability for tumor cells due to its short range and high energy deposition in the tumor micrometastasis focus. However, the secondary myelofibrosis (SMF) associated with Ac-225-PSMA-617 treatment is a significant concern. We present a case of metastatic castration-resistant prostate cancer (mCRPC) who developed pancytopenia following the Ac-225-PSMA-617 treatment period, a bone marrow biopsy confirmed SMF and remained uncorrected after multiple component transfusions and symptomatic supportive therapy. Ac-225-PSMA-617 has demonstrated promising therapeutic efficacy in the management of advanced PCa; however, the potential risks associated with SMF necessitate careful consideration. Through comprehensive analysis of this clinical case and comparative evaluation with the existing literature, this study highlights the need to balance clinical benefit with increased vigilance for treatment-related adverse events.<\/jats:p>","DOI":"10.3389\/fmed.2025.1569143","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:39:23Z","timestamp":1752644363000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Ziye","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000531246","article-title":"Efficacy and safety of actinium-225 prostate-specific membrane antigen radioligand therapy in metastatic prostate cancer: a systematic review and metanalysis","volume":"32","author":"Parida","year":"2023","journal-title":"Med Princ Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.revmed.2020.08.018","article-title":"Myelofibrosis: a review","volume":"42","author":"Genthon","year":"2021","journal-title":"Rev Med Interne"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","article-title":"Hematologic toxicity profile and efficacy of [(225)Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer","volume":"49","author":"Lawal","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B6","doi-asserted-by":"publisher","first-page":"796657","DOI":"10.3389\/fonc.2022.796657","article-title":"Efficacy and safety of (225)Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13287-024-03853-7","article-title":"Insights into ionizing radiation-induced bone marrow hematopoietic stem cell injury","volume":"15","author":"Zhang","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41181-025-00333-y","article-title":"Hematological toxicity of [(225)Ac]Ac-PSMA-617 and [(177)Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model","volume":"10","author":"Vilangattil","year":"2025","journal-title":"EJNMMI Radiopharm Chem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.7150\/thno.96403","article-title":"Actinium-225 targeted alpha particle therapy for prostate cancer","volume":"14","author":"Bidkar","year":"2024","journal-title":"Theranostics."},{"key":"B12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12149-018-1230-7","article-title":"Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)","volume":"32","author":"Hosono","year":"2018","journal-title":"Ann Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.22038\/AOJNMB.2022.64964.1454","article-title":"Therapeutic outcomes of (177)Lu-PSMA targeted therapy in patients with metastatic castration-resistant prostate cancer: a single-center study","volume":"11","author":"Mirshahvalad","year":"2023","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1097\/RLU.0000000000004149","article-title":"Delayed nephrotoxicity after 225Ac-PSMA-617 radioligand therapy","volume":"47","author":"Satapathy","year":"2022","journal-title":"Clin Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1080\/10428194.2021.2010068","article-title":"Novel therapeutics and targets in myelofibrosis","volume":"63","author":"Waksal","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcancer.2022.09.004","article-title":"TGF-\u03b2 in developmental and fibrogenic EMTs","volume":"86","author":"Lee","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/mirt.galenos.2021.63308","article-title":"Relative efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in prostate cancer based on subcellular dosimetry","volume":"31","author":"Lee","year":"2022","journal-title":"Mol Imaging Radionucl Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1060922","DOI":"10.3389\/fmed.2022.1060922","article-title":"Prostate specific membrane antigen binding radiopharmaceuticals: current data and new concepts","volume":"9","author":"Sartor","year":"2022","journal-title":"Front Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"(225)Ac-PSMA-617\/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/pharmaceutics13050722","article-title":"Efficacy and safety of [(225)Ac]Ac-PSMA-617 augmented [(177)Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis","volume":"13","author":"Rosar","year":"2021","journal-title":"Pharmaceutics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1007\/s00259-023-06340-y","article-title":"Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study","volume":"50","author":"Ballal","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1569143\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:39:24Z","timestamp":1752644364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1569143\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":24,"alternative-id":["10.3389\/fmed.2025.1569143"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1569143","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"article-number":"1569143"}}